Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis

BACKGROUNDEvidence regarding the feasibility of Janus kinase inhibitors tapering following adequate response in moderate-to-severe atopic dermatitis (AD) remains limited, and no head-to-head comparisons of tapering regimens have been conducted.

OBJECTIVETo evaluate the feasibility of 24-week abrocitinib tapering in moderate-to-severe AD patients having achieved adequate response and compare 2 tapering methods.

METHODSThis retrospective study enrolled moderate-to-severe AD patients who achieved adequate clinical response with abrocitinib and underwent tapering over 24 weeks via dose reduction or interval extension.

RESULTSA total of 78 patients (36 dose reduction, 42 interval extension) were included, and successful tapering was achieved in 76 (97.4%). Nonrelapse rates were 97.4% and 91.0% at weeks 12 and 24, respectively. At week 24, mean cumulative dose was reduced by 9892 mg (6908 mg vs 16,800 mg standard), with cost savings of ¥ 2899.5 (¥ 2016.7 vs ¥ 4916.2 projected). Patients with extended dosing intervals had significantly higher strategy-switch rates due to disease fluctuation [28.6% (12/42) vs 8.3% (3/36), P = .041].

LIMITATIONSThe single-center retrospective design, small sample size, and relatively short follow-up duration.

CONCLUSIONTwenty-four-week abrocitinib tapering appears feasible in well-responding moderate-to-severe AD patients, reducing treatment burden while preserving efficacy.

Abstract from PubMed